

Career Development Funding Opportunity Announcement Edits for NOT-OD-17-114

September 14, 2017

Impacted FOAs

All active Career Development FOAs with due dates on or after January 25, 2018 will be updated with the following exceptions:

- Parent announcements will NOT be updated since they will be reissued (with new FOA numbers) for due dates on or after January 25.
- FOAs that will allow applications proposing clinical trials will NOT be updated since they will be reissued (with new FOA numbers) for due dates on or after January 25.

Specific changes to Career Development announcements include:

- In preparation for clinical trial-specific FOA policy ([NOT-OD-17-043](#)), we will add clinical trial allowability indicator in table in FOA *Part 2, Section II. Award Information*.

Clinical Trial?	Clinical Trials Not Allowed for due dates on or after January 25, 2018: Only accepting applications that do not propose independent clinical trials Note: Applicants may propose to gain experience in a clinical trial led by a mentor/co-mentor as part of their research career development. Need help determining whether you are doing a clinical trial?
------------------------	---

- In preparation for FORMS-E application forms ([NOT-OD-17-062](#) and [NOT-HS-17-015](#)), we will add text to PHS Inclusion Enrollment Report form instructions in *Part 2, Section IV. Application and Submission Information* to indicate the form is only available in FORMS-D application packages for due dates on or before January 24, 2018.

Old text:

PHS Inclusion Enrollment Report

When conducting clinical research, follow all instructions for completing PHS Inclusion Enrollment Report as described in the SF424 (R&R) Application Guide.

New text:

PHS Inclusion Enrollment Report

Form only available in FORMS-D application packages for use with due dates on or before January 24, 2018.

When conducting clinical research, follow all instructions for completing PHS Inclusion Enrollment Report as described in the SF424 (R&R) Application Guide.

- In preparation for FORMS-E application forms ([NOT-OD-17-062](#) and [NOT-HS-17-015](#)), we will add text for the PHS Human Subjects and Clinical Trials Information form and instructions in *Part 2, Section IV. Application and Submission Information* and indicate the form is only available in FORMS-E application packages for due dates on or after January 25, 2018.

Sample text insert:

PHS Human Subjects and Clinical Trials Information

Form only available in FORMS-E application packages for use with due dates on or after January 25, 2018.

When involving NIH-defined human subjects research, clinical research, and/or clinical trials (and when applicable, clinical trials research experience) follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the SF424 (R&R) Application Guide, with the following additional instructions:

If you answered “Yes” to the question “Are Human Subjects Involved?” on the R&R Other Project Information form, you must include at least one human subjects study record using the **Study Record: PHS Human Subjects and Clinical Trials Information** form or a **Delayed Onset Study** record.

Study Record: PHS Human Subjects and Clinical Trials Information

All instructions in the SF424 (R&R) Application Guide must be followed with the following additional instructions:

- For FOAs that do not allow independent clinical trials, do not complete Section 4 – Protocol Synopsis information or Section 5 – Other Clinical Trial-related Attachments.

Delayed Onset Study

All instructions in the SF424 (R&R) Application Guide must be followed.

- Remove the following note since the referenced changes are incorporated into the announcement text as part of this update (does not apply to K02, K05 or K24).

Important Update: See [NOT-OD-16-012](#) and [NOT-OD-16-006](#) for updated review language for applications for due dates on or after January 25, 2016.

- To align announcements with Rigor and Transparency policy ([NOT-OD-16-012](#)), we will add the following rigor and transparency questions to the Research Plan section in *Part 2, Section V. Application Review Information* (does not apply to K02, K05 or K24):
 - Is there a strong scientific premise for the project?
 - Applies only to: K01, K07, K08, K22, K23, K25, K99/R00
 - Has the candidate presented strategies to ensure a robust and unbiased approach, as appropriate for the work proposed?
 - Has the candidate presented adequate plans to address relevant biological variables, such as sex, for studies in vertebrate animals or human subjects?
- To align announcements with Rigor and Transparency policy ([NOT-OD-16-012](#)), we will add the following Authentication of Key Biological and/or Chemical Resources section to the Additional Review Criteria in *Part 2, Section V. Application Review Information* (does not apply to K02, K05 or K24):

Authentication of Key Biological and/or Chemical Resources

For projects involving key biological and/or chemical resources, reviewers will comment on the brief plans proposed for identifying and ensuring the validity of those resources.

- To align announcements with recent vertebrate animals changes ([NOT-OD-16-006](#)), we will replace the Vertebrate Animals section of the Additional Review Criteria in *Part 2, Section V. Application Review Information* as follows:

Old text:

The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following five points: (1) proposed use of the animals, and species, strains, ages, sex, and numbers to be used; (2) justifications for the use of animals and for the appropriateness of the species and numbers proposed; (3) adequacy of veterinary care; (4) procedures for limiting discomfort, distress, pain and injury to that which is unavoidable in the conduct of scientifically sound research including the use of analgesic, anesthetic, and tranquilizing drugs and/or comfortable restraining devices; and (5) methods of euthanasia and reason for selection if not consistent with the AVMA Guidelines on Euthanasia. For additional information on review of the Vertebrate Animals section, please refer to the [Worksheet for Review of the Vertebrate Animal Section](#).

New text:

The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following criteria: (1) description of proposed procedures involving animals, including species, strains, ages, sex, and total number to be used; (2) justifications for the use of animals versus alternative models and for the appropriateness of the species proposed; (3) interventions to minimize discomfort, distress, pain and injury; and (4) justification for euthanasia method if NOT consistent with the AVMA Guidelines for the Euthanasia of Animals. Reviewers will assess the use of chimpanzees as they would any other application proposing the use of vertebrate animals. For additional information on review of the Vertebrate Animals section, please refer to the [Worksheet for Review of the Vertebrate Animal Section](#).